On 22nd May 2026, Siemens Healthineers officially unveiled the Symbia Pro.Specta SPECT/CT system during an in-booth launching ceremony at the 6th Siloam Oncology Summit 2026 at the Shangri-La Hotel in Jakarta, Indonesia. The introduction of the Symbia Pro.specta marks an important milestone as the first Siemens Healthineers SPECT/CT system within the Siloam Hospitals Group, further strengthening both organizations’ shared commitment to advancing precision oncology, personalized treatment, and improved patient outcomes in Indonesia.
Cancer remains a major health challenge in Indonesia, where the need for earlier detection and more personalized treatment approaches is growing. According to GLOBOCAN 2022 (International Agency for Research on Cancer/WHO), Indonesia recorded approximately 408,661 new cancer cases and 242,988 cancer-related deaths, with breast, lung, colorectal, cervical, and liver cancers among the most common1. In addition, many patients are diagnosed at advanced stages, reflecting persistent challenges in early detection and access to comprehensive care. These realities highlight the urgency of strengthening oncology capabilities across the country.
This context aligns closely with the overarching theme of the 6th Siloam Oncology Summit 2026, “United by Unique,” emphasizing that every cancer journey is different and requires individualized approaches to care. Guided by the shared theme, the Summit brought together clinicians, researchers, and healthcare stakeholders to strengthen collaboration, accelerate innovation, and advance patient-centric oncology services in Indonesia.
The launch of the Symbia Pro.Specta directly supports this vision by enabling more precise diagnostics and personalized treatment planning. As a next-generation hybrid imaging system, the technology combines functional and anatomical imaging to provide deeper insights into biological processes within the body. This allows clinicians not only to detect disease earlier but also to better understand tumor behavior and tailor treatment decisions to individual patients.
By moving beyond conventional imaging, the Symbia Pro.Specta plays a critical role in advancing precision medicine, particularly in the emerging field of theranostics, where diagnosis and therapy are closely integrated. The system supports improved accuracy in disease characterization, enhances confidence in clinical decision-making, and contributes to more targeted and effective therapies—ultimately enabling a more personalized approach to cancer care.
“The launch of the Symbia Pro.Specta at the 6th Siloam Oncology Summit 2026 represents a meaningful step forward in advancing precision medicine in Indonesia. At Siemens Healthineers, we believe that every patient is unique, and their care pathway should reflect that individuality. By enabling deeper insights into disease at a molecular level, we support clinicians in delivering more accurate diagnoses and personalized treatment. Together with Siloam Hospitals Group, we are committed to elevating cancer care in Indonesia through innovation, clinical excellence, and improved access to advanced healthcare technologies.”
“As a leading healthcare provider in Indonesia, MRCCC Siloam Semanggi remains committed to continuously advancing our oncology services. The introduction of the Symbia Pro.Specta strengthens our capabilities in nuclear medicine and precision imaging, enabling more accurate diagnosis and more individualized treatment planning. Through our collaboration with Siemens Healthineers, we continue to enhance integrated, patient-centered cancer care across our network.”
Beyond the system launch, Siemens Healthineers also presented its comprehensive oncology portfolio at the Summit, demonstrating its role as a holistic partner across the entire cancer care continuum. From screening and early detection using AI-enabled imaging, to advanced diagnostics such as PET/CT and SPECT/CT, as well as solutions for radiation therapy, interventional oncology, surgery, and follow-up care and survivorship, the company’s integrated ecosystem is designed to support every stage of the patient journey.
This end-to-end approach reflects the commitment of Siemens Healthineers to enable healthcare providers like MRCCC Siloam Semanggi to deliver connected, efficient, and patient-centric care. By integrating technology, data, and clinical workflows, the collaboration aims to improve diagnostic accuracy, optimize treatment pathways, and ultimately enhance long-term outcomes for cancer patients in Indonesia.
Through this partnership, Siemens Healthineers and MRCCC Siloam Semanggi reaffirm their shared vision to elevate cancer care in Indonesia—expanding access, advancing precision medicine, and improving the lives of patients nationwide.
About Siemens Healthineers
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.
About MRCCC Siloam Hospital Semanggi
The Mochtar Riady Comprehensive Cancer Center (MRCCC) Siloam is Indonesia’s leading private cancer hospital, accredited by the Joint Commission International (JCI) and consistently recognized among the nation’s top oncology institutions. It has also been named by Newsweek for two consecutive years as one of Asia Pacific’s best specialized oncology centers. Equipped with advanced infrastructure—including linear accelerators, brachytherapy, PET and SPECT scanners, an in-house cyclotron, and innovative therapies such as Lu-PSMA and thyroid ablation—MRCCC provides some of the country’s most advanced cancer treatment options, including stem cell transplants and other complex procedures.
Beyond technology, MRCCC is distinguished by its patient-centered multidisciplinary team (MDT) approach, integrating expertise across medical oncology, surgical oncology, radiology, pathology, and nuclear medicine. While MDT implementation in Indonesia faces challenges such as a limited pool of oncologists and varying levels of collaboration, MRCCC has successfully built a coordinated care model. This commitment reflects the hospital’s leadership and medical team’s dedication to delivering world-class, comprehensive cancer care to every patient.
Contact for media enquiries, please get in touch with:
Siemens Healthineers Indonesia
Evan Akira Zuraida
Head of Communications, Indonesia
E-mail: evan.akira@siemens-healthineers.com
MRCCC Siloam Semanggi
Joanna Halim
Head of Marketing & Communications
E-mail: Joanna.halim@siloamhospitals.com